Pure Global

Rheumatoid Factor IgM - India CDSCO Medical Device Registration

Rheumatoid Factor IgM is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/IVD/2021/000558_f44fda19e10bd77e16962358502a0e82_7ba219aab9c0f7206003c5cdcaab4edb. This device is marketed under the brand name Anti-Gliadin IgG. The license holder is Sebia Diagnostics India Pvt. Ltd., and it is classified as Device Class Class B. The approving authority is CDSCO.

This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.

Free Database
Powered by Pure Global AI
CDSCO Registered
Class Class B
Rheumatoid Factor IgM
UID: IMP/IVD/2021/000558_f44fda19e10bd77e16962358502a0e82_7ba219aab9c0f7206003c5cdcaab4edb

Brand Name

Anti-Gliadin IgG

Device Class

Class B

Approving Authority

CDSCO

Product Information

Rheumatoid Factor IgM is an ELISA-based test system for the quantitative measurement of IgM class rheumatoid factor in human serum or plasma samples. This product is intended for professional in vitro diagnostic use only. The test is used as an aid in the differential diagnosis of rheumatoid arthritis (Anti-Gliadin IgG), and presence of rheumatoid factors (Anti-Gliadin IgG) is an integral part of the current ACR criteria for classification of RA. In established RA, high titres of serum IgG and especially IgM RF indicate poor prognosis. The presence of either IgG or IgA RF in patients with long-standing RA may be a prognostic indicator of systemic manifestations. Evaluation of a test result should always take into account all clinical and laboratory findings

Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing